NCT04989504

Brief Summary

This phase III trial studies how well Mepitel Film works in reducing radiation dermatitis (redness and peeling) in patients with breast cancer during radiation therapy after a mastectomy. Mepitel Film may reduce the severity of skin redness and peeling in the area of radiation.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
216

participants targeted

Target at P25-P50 for phase_3

Timeline
34mo left

Started Jul 2022

Longer than P75 for phase_3

Geographic Reach
1 country

49 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
Jul 2022Feb 2029

First Submitted

Initial submission to the registry

July 26, 2021

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 4, 2021

Completed
12 months until next milestone

Study Start

First participant enrolled

July 26, 2022

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 29, 2024

Completed
11 months until next milestone

Results Posted

Study results publicly available

April 29, 2025

Completed
3.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2029

Expected
Last Updated

April 29, 2025

Status Verified

April 1, 2025

Enrollment Period

1.8 years

First QC Date

July 26, 2021

Results QC Date

March 31, 2025

Last Update Submit

April 23, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Serially Measured Patient-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores

    Scores obtained at baseline (i.e. prior to the start of radiation), during weekly radiation therapy, at 10 (±4) days post-radiation therapy, and at 3-months post radiation therapy. At a given measurement time point, a patient-completed mRISRAS score ranges from 0 to 12, where higher scores correspond to increased radiation-induced skin reactions. The effect of the Mepitel Film in reducing the severity of radiation dermatitis will be defined as the between-arm difference in the summary statistic area under the curve obtained from a repeated-measures (means) mixed model.

    Up to 5 months

Secondary Outcomes (3)

  • Centralized, Blinded Provider-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores Obtained From a Blinded Grading of the Photographs Taken at the End of Radiation Therapy

    Up to 2 months

  • Serially Measured Non-blinded Institutional Provider-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores

    Up to 5 months

  • Serially Measured Combined Patient- and Provider-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores

    Up to 5 months

Study Arms (2)

Arm I (standard of care)

ACTIVE COMPARATOR

Patients receive standard of care skin management during radiation therapy for up to 6 weeks.

Other: Best PracticeOther: Quality-of-Life AssessmentOther: Questionnaire Administration

Arm II (Mepitel Film)

EXPERIMENTAL

Patients receive Mepitel Film applied to breast or chest wall every week before radiation therapy for up to 6 weeks.

Device: Wound Dressing MaterialOther: Quality-of-Life AssessmentOther: Questionnaire Administration

Interventions

Receive standard of care

Also known as: Standard of Care
Arm I (standard of care)

Apply Mepitel Film

Arm II (Mepitel Film)

Ancillary studies

Arm I (standard of care)Arm II (Mepitel Film)

Ancillary studies

Arm I (standard of care)Arm II (Mepitel Film)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Histologic confirmation of breast malignancy with TNM staging.
  • Patients must have undergone a mastectomy with or without reconstruction within the past 120 days if not receiving adjuvant therapy, or within 60 days after completion of the last dose of chemotherapy.
  • No prior radiotherapy to any portion of the planned treatment site.
  • No documented history of adhesive or tape allergy.
  • Patients must be scheduled to receive conventionally fractionated photon-based radiation. Patients planning brachytherapy within the treatment field, and patients scheduled to receive bilateral radiation or hypofractionated radiation are not eligible.
  • No active rash or pre-existing dermatitis within the treatment field.
  • No co-existing medical conditions resulting in life expectancy \< 2 years.
  • No active collagen vascular diseases (i.e. lupus erythematosus, scleroderma, dermatomyositis).
  • No concomitant cytotoxic chemotherapy. Endocrine therapy and HER2 directed therapies are allowed.
  • No current inflammatory breast cancer, or gross dermal involvement at initiation of radiotherapy.
  • No previous history of organ or bone marrow transplant.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • In order to complete the mandatory patient-completed measures, participants must be able to speak and read English.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (49)

Fremont - Rideout Cancer Center

Marysville, California, 95901, United States

Location

Gene Upshaw Memorial Tahoe Forest Cancer Center

Truckee, California, 96161, United States

Location

Beebe South Coastal Health Campus

Frankford, Delaware, 19945, United States

Location

Helen F Graham Cancer Center

Newark, Delaware, 19713, United States

Location

Medical Oncology Hematology Consultants PA

Newark, Delaware, 19713, United States

Location

Beebe Health Campus

Rehoboth Beach, Delaware, 19971, United States

Location

John Fitzgerald Kennedy Medical Center

Atlantis, Florida, 33462, United States

Location

McFarland Clinic - Ames

Ames, Iowa, 50010, United States

Location

Mercy Hospital

Cedar Rapids, Iowa, 52403, United States

Location

Oncology Associates at Mercy Medical Center

Cedar Rapids, Iowa, 52403, United States

Location

Mercy Cancer Center-West Lakes

Clive, Iowa, 50325, United States

Location

Iowa Methodist Medical Center

Des Moines, Iowa, 50309, United States

Location

Medical Oncology and Hematology Associates-Des Moines

Des Moines, Iowa, 50309, United States

Location

Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314, United States

Location

MaineHealth Coastal Cancer Treatment Center

Bath, Maine, 04530, United States

Location

Maine Medical Center-Bramhall Campus

Portland, Maine, 04102, United States

Location

MaineHealth Cancer Care Center of York County

Sanford, Maine, 04073, United States

Location

Maine Medical Center- Scarborough Campus

Scarborough, Maine, 04074, United States

Location

Anne Arundel Medical Center

Annapolis, Maryland, 21401, United States

Location

University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States

Location

Sinai Hospital of Baltimore

Baltimore, Maryland, 21215, United States

Location

Central Maryland Radiation Oncology in Howard County

Columbia, Maryland, 21044, United States

Location

UM Baltimore Washington Medical Center/Tate Cancer Center

Glen Burnie, Maryland, 21061, United States

Location

UM Saint Joseph Medical Center

Towson, Maryland, 21204, United States

Location

Saint Joseph Mercy Hospital

Ann Arbor, Michigan, 48106, United States

Location

Saint Joseph Mercy Brighton

Brighton, Michigan, 48114, United States

Location

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154, United States

Location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Delbert Day Cancer Institute at PCRMC

Rolla, Missouri, 65401, United States

Location

Mercy Hospital Springfield

Springfield, Missouri, 65804, United States

Location

Mercy Hospital Saint Louis

St Louis, Missouri, 63141, United States

Location

Billings Clinic Cancer Center

Billings, Montana, 59101, United States

Location

Glens Falls Hospital

Glens Falls, New York, 12801, United States

Location

Dickstein Cancer Treatment Center

White Plains, New York, 10601, United States

Location

Altru Cancer Center

Grand Forks, North Dakota, 58201, United States

Location

Holy Redeemer Hospital and Medical Center

Meadowbrook, Pennsylvania, 19046, United States

Location

AnMed Health Cancer Center

Anderson, South Carolina, 29621, United States

Location

Tidelands Georgetown Memorial Hospital

Georgetown, South Carolina, 29440, United States

Location

Saint Francis Hospital

Greenville, South Carolina, 29601, United States

Location

Saint Francis Cancer Center

Greenville, South Carolina, 29607, United States

Location

Gibbs Cancer Center-Pelham

Greer, South Carolina, 29651, United States

Location

MUSC Health Tidelands Health Radiation Therapy Center

Murrells Inlet, South Carolina, 29576, United States

Location

Spartanburg Medical Center

Spartanburg, South Carolina, 29303, United States

Location

Doctor's Hospital of Laredo

Laredo, Texas, 78041, United States

Location

University of Utah Sugarhouse Health Center

Salt Lake City, Utah, 84106, United States

Location

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States

Location

ThedaCare Regional Cancer Center

Appleton, Wisconsin, 54911, United States

Location

Aspirus Regional Cancer Center

Wausau, Wisconsin, 54401, United States

Location

Aspirus Cancer Care - Wisconsin Rapids

Wisconsin Rapids, Wisconsin, 54494, United States

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Practice Guidelines as TopicStandard of CareBandages

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Guidelines as TopicQuality Assurance, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and EvaluationQuality Indicators, Health CareEquipment and Supplies

Results Point of Contact

Title
Dr. Kimberly Corbin
Organization
Mayo Clinic

Study Officials

  • Kimberly Corbin, MD

    Mayo Clinic

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 26, 2021

First Posted

August 4, 2021

Study Start

July 26, 2022

Primary Completion

May 29, 2024

Study Completion (Estimated)

February 15, 2029

Last Updated

April 29, 2025

Results First Posted

April 29, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will share

Locations